Top Marijuana Stocks That Can Make You Money In 2026Much of the talk surrounding marijuana stocks trading better is based on new reform. Right now, many are waiting to see what Donald Trump will do regarding making cannabis a Class 3 substance. This news has set the cannabis sector ablaze. Right now, people are focusing on how to take advantage of this and make a profit. With a new year around the corner, using speculation on reform measures is a strategy some will take towards making a profit.Often, when n ...

Terms of Use Privacy Notice Accessibility About Us Reviews Site Map Your Ad Choices Advertising Contact us IBD Stock Charts IBD Stock Checkup Stock Quotes Stock Market Today The Big Picture My Stock Lists IBD Live Leaderboard SwingTrader MarketSurge IBD Digital MarketDiem The Wall Street Journal Barron's MarketWatch Dow Jones Smart Money Connect With Us On stocks they discuss. We make no representations or warranties regarding the advisability of investing in any particular securities or utilizing any speci ...

The company and many of its peers saw dramatic lifts on the back of new Presidential remarks.Investors caught quite the serious buzz from marijuana stocks on Tuesday, thanks largely to President Trump's strongest indication so far that he will get the ball rolling on the drug's rescheduling. One title that wafted well higher in price was Curaleaf Holdings (CURLF +23.18%), which was up by almost 25% when the smoke cleared. Will the Trump card be played?This came in an answer to a reporter's question whether ...

For hardly the first time in recent days, investors have become excited about the prospect of a significant change in U.S. drug laws.Will he or won't he? This is the question that's been front of mind for many marijuana stock investors over the past few days, as both credible media reports and President Trump himself fueled speculation that he will begin the process of decriminalizing the drug. Comments from the President late Monday injected new bullishness into weed stocks the following day. Sector mainst ...

After many false starts, investors are once again betting that marijuana businesses are close to seeing federal restrictions ease. ...

Core Insights - Marijuana stocks present both short-term and long-term investment opportunities, with current low prices creating a favorable buying environment before the new year [1] - The cannabis market is influenced by reform measures, with speculation rising around potential legislative changes, such as the rescheduling of cannabis to Class 3 [2] - The expansion of cannabis legalization in various states and the growth of markets in Canada and Europe are expected to positively impact marijuana stock trading [3] Company Highlights - **Green Thumb Industries Inc.** reported Q3 2025 revenue of $291.4 million, a 1.6% increase year-over-year, with cash at quarter end totaling $226.2 million and GAAP net income of $23.3 million [10] - **Cresco Labs Inc.** is expanding its operations into Germany, launching its flagship flower brand, which reflects its growth strategy beyond the U.S. market [11][13] - **Verano Holdings Corp.** received a conditional license to operate in Texas, allowing it to cultivate, process, and dispense medical cannabis, pending final approval [14][16]

Marijuana stocks surged Friday after reports that Trump could sign an executive order reclassifying cannabis. ...

Core Insights - The U.S. cannabis industry is nearing a significant inflection point, with ongoing federal policy discussions, particularly regarding cannabis rescheduling, which could lead to reduced tax burdens and improved profitability for operators [1][2] - Recent state-level expansions of adult-use programs and medical access frameworks, along with renewed federal banking reform discussions, are contributing to a growing momentum for legalization [2][6] - Companies with strong balance sheets and retail scale, such as Trulieve, Green Thumb Industries, and Cresco Labs, are well-positioned for growth as federal reforms progress [5][6] Industry Overview - The U.S. cannabis industry is evolving amidst regulatory uncertainty, with large multi-state operators focusing on long-term growth through scale, efficiency, and strong balance sheets [6][20] - Federal reform may be gradual, but even incremental changes could unlock significant value for cannabis companies [5][20] Company Profiles Trulieve Cannabis Corp. - Trulieve is one of the largest U.S. cannabis operators, with over 180 dispensaries, primarily in Florida, and a strong market share [9][10] - The company emphasizes cash flow stability, with steady revenue and strong gross margins, while maintaining disciplined capital expenditures and avoiding excessive dilution [12][10] Green Thumb Industries Inc. - Green Thumb operates over 100 dispensaries and focuses on branded consumer products, which differentiates it from competitors [13][14] - The company has maintained positive net income and strong operating cash flow, with a conservative balance sheet and manageable debt levels [15][14] Cresco Labs Inc. - Cresco is a vertically integrated operator with a strong wholesale focus, operating retail locations under the Sunnyside brand and maintaining a presence in key states [16][17] - The company has focused on stabilization and efficiency, with steady revenue and improving gross margins, while managing operating expenses carefully [19][18]

Information in Investor's Business Daily is for informational and educational purposes only and should not be construed as an offer, recommendation, solicitation, or rating to buy or sell securities. The information has been obtained from sources we believe to be reliable, but we make no guarantee as to its accuracy, timeliness, or suitability, including with respect to information that appears in closed captioning. Historical investment performances are no indication or guarantee of future success or perfo ...

The U.S. marijuana industry has stagnated for year, languishing under federal inaction on reclassification or decriminalization. Classified as a Schedule I drug under the Controlled Substances Act — alongside hard drugs like heroin and LSD — cannabis is deemed to have no accepted medical use and high abuse potential. This status blocks research, interstate commerce, and access to basic banking services for operators. Meanwhile, 38 states have legalized medical marijuana, and 24 allow recreational use, creat ...